Lawood & Co’s IGC Pharma IGC Stock Holding History

Lawood & Co’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.4K	Hold	75,000	–	–	0.01%	95
2026 Q1	$19.7K	Hold	75,000	–	–	0.02%	90
2025 Q4	$21.1K	Buy	+75,000	New	+$26.7K	0.02%	93

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lawood & Co's IGC Position: Q2 2026 in Review

Lawood & Co held its IGC Pharma (IGC) position steady in Q2 2026 at 75,000 shares worth $20.4K. The position accounts for 0.01% of the portfolio, ranked #95.

Lawood & Co first reported a position in IGC in Q4 2025 and has held it in 3 quarters since. The position peaked at $21.1K in Q4 2025. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

Lawood & Co held 75,000 shares of IGC Pharma worth $20.4K as of Q2 2026.
Lawood & Co left its IGC Pharma share count unchanged in Q2 2026.
IGC Pharma made up 0.01% of Lawood & Co's portfolio in Q2 2026, its #95 holding.
Lawood & Co first reported a position in IGC Pharma in Q4 2025 and has held it in 3 quarters since.
Lawood & Co's IGC Pharma position peaked at $21.1K in Q4 2025.
36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Lawood & Co's 13F filing for Q2 2026, filed 13 Jul 2026.